Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress Sep 14, 2020 8:30am EDT
Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188 Sep 11, 2020 8:00am EDT
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors Sep 08, 2020 7:00am EDT
Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020 Sep 01, 2020 7:00am EDT
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress Aug 05, 2020 4:01pm EDT
Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 Jul 29, 2020 4:01pm EDT
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares Jun 24, 2020 4:34pm EDT
Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis Jun 17, 2020 8:47am EDT
Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format Jun 05, 2020 4:15pm EDT
